(United States, Nevada, Las Vegas), DelveInsight’s “Graft versus host disease (GVHD) Pipeline Insight, 2023” report provides comprehensive insights about 60+ GvHD companies and 60+ pipeline drugs in the Graft versus host disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Graft Versus Host Disease Pipeline Report
Over 60+ companies and 60+ pipeline drugs in Graft Versus Host Disease are in various stages of development, and their anticipated acceptance in the Graft Versus Host Disease market would significantly increase market revenue.
Leading Graft Versus Host Disease companies developing novel drug candidates to improve the Graft Versus Host Disease treatment landscape include Biocon, Medac GmbH, Maat Pharma, ElsaLys Biotech, GliaSyndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others.
Promising Graft Versus Host Disease pipeline therapies in various stages of development include Teplizumab, ASC930, and others.
Graft Versus Host Disease Overview
Graft-versus-host disease is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant. Cells of the immune system are trained early to differentiate between “self” cells and “non-self” cells. The ability to recognize “non-self” cells depends on a set of genes known as the histocompatibility genes that provide instructions for making a group of related proteins known as major histocompatibility complex (MHC proteins) or human leukocyte antigens.
Graft Versus Host Disease Pipeline Analysis: Drug Profile
Teplizumab: Prevention Bio
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Discover more about the emerging Graft Versus Host Disease drugs @ Graft Versus Host Disease Treatment Drugs
Graft Versus Host Disease Pipeline Therapies and Key Companies
ASC930: ASC Therapeutics
And many others
Graft Versus Host Disease Pipeline Therapeutics Assessment
Phases
DelveInsight’s Graft versus host disease pipeline report covers around 60+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Molecule Type
Graft versus host disease Products have been categorized under various Molecule types such as
Small molecule
Cell Therapy
Peptides
Polymer
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Graft Versus Host Disease Pipeline Report
Coverage: Global
Key Graft Versus Host Disease Companies: Biocon, Medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera and many others.
Key Graft Versus Host Disease Pipeline Therapies: Teplizumab, ASC930, and many others
Find out more about the Graft Versus Host Disease treatment options in development@ Graft Versus Host Disease Clinical Trials
Table of Contents
1. Graft Versus Host Disease Introduction
2. Graft Versus Host Disease Executive Summary
3. Graft Versus Host Disease Overview
4. Graft Versus Host Disease Pipeline Therapeutics
5. Graft Versus Host Disease Late-Stage Products (Phase III)
6. Graft Versus Host Disease Mid-Stage Products (Phase II)
7. Graft Versus Host Disease Early Stage Products (Phase I/II)
8. Graft Versus Host Disease Preclinical Stage Products
9. Graft Versus Host Disease Discovery Stage Products
10. Graft Versus Host DiseaseTherapeutic Assessment
11. Graft Versus Host Disease Inactive Products
12. Graft Versus Host Disease Collaborations Assessment- Licensing / Partnering / Funding
13. Graft Versus Host Disease Unmet Needs
14. Graft Versus Host Disease Market Drivers and Barriers
15. Appendix
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services